Home » Stocks » XGN

Exagen Inc. (XGN)

Stock Price: $14.93 USD -0.57 (-3.68%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 262.35M
Revenue (ttm) 41.98M
Net Income (ttm) -16.69M
Shares Out 12.63M
EPS (ttm) -72.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $14.93
Previous Close $15.50
Change ($) -0.57
Change (%) -3.68%
Day's Open 15.50
Day's Range 14.93 - 15.67
Day's Volume 20,740
52-Week Range 10.29 - 24.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases The suite of innovative biomarker assays seeks to...

2 days ago - GlobeNewsWire

Exagen Inc. (XGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 days ago - Zacks Investment Research

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awarene...

3 days ago - GlobeNewsWire

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the...

1 week ago - GlobeNewsWire

SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today tha...

1 month ago - GlobeNewsWire

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten publ...

1 month ago - GlobeNewsWire

SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 s...

1 month ago - GlobeNewsWire

SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and othe...

1 month ago - GlobeNewsWire

Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.18% and 16.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters

1 month ago - GlobeNewsWire

Exagen (XGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Exagen Inc. (XGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Exagen Inc. (XGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

2 months ago - Zacks Investment Research

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the mark...

2 months ago - GlobeNewsWire

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which takes p...

2 months ago - GlobeNewsWire

SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnosti...

3 months ago - GlobeNewsWire

SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that...

3 months ago - GlobeNewsWire

Record Testing Revenue, Adopters and AVISE CTD® Volumes

3 months ago - GlobeNewsWire

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that...

4 months ago - GlobeNewsWire

SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that...

4 months ago - GlobeNewsWire

Exagen (XGN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.

Other stocks mentioned: TMDX, MYO
4 months ago - Zacks Investment Research

SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that...

5 months ago - GlobeNewsWire

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune disea...

5 months ago - GlobeNewsWire

Exagen Inc. (XGN) CEO Ron Rocca on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Shares of Exagen (NASDAQ:XGN) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 83.65% year over year to ($0.34), which beat the estim...

5 months ago - Benzinga

Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing

5 months ago - GlobeNewsWire

SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that...

5 months ago - GlobeNewsWire

SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a ne...

6 months ago - GlobeNewsWire

SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that...

6 months ago - GlobeNewsWire

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today it w...

6 months ago - GlobeNewsWire

SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the ...

6 months ago - GlobeNewsWire

SAN DIEGO, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune di...

7 months ago - GlobeNewsWire

SAN DIEGO, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, is proud to annou...

7 months ago - GlobeNewsWire

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced t...

7 months ago - GlobeNewsWire

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced t...

8 months ago - GlobeNewsWire

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a ...

9 months ago - GlobeNewsWire

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced th...

9 months ago - GlobeNewsWire

Exagen Inc. (XGN) CEO Ron Rocca on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Testing Experiencing Monthly Sequential Improvement Record Gross Margins of 63%

9 months ago - GlobeNewsWire

AVISE Tests Now Available to 6 Million Humana Military Beneficiaries AVISE Tests Now Available to 6 Million Humana Military Beneficiaries

9 months ago - GlobeNewsWire

SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced th...

9 months ago - GlobeNewsWire

Exagen (XGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced it...

10 months ago - GlobeNewsWire

SAN DIEGO, June 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a ...

11 months ago - GlobeNewsWire

Exagen Inc. (XGN) CEO Ron Rocca on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Exagen Inc. (XGN) CEO Ron Rocca on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced t...

1 year ago - GlobeNewsWire

SAN DIEGO, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmun...

1 year ago - GlobeNewsWire

SAN DIEGO, CA, March 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmun...

1 year ago - GlobeNewsWire

About XGN

Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various conne... [Read more...]

Industry
Diagnostics & Research
IPO Date
Sep 19, 2019
CEO
Fortunato Rocca
Employees
181
Stock Exchange
NASDAQ
Ticker Symbol
XGN
Full Company Profile

Financial Performance

In 2020, Exagen's revenue was $41.98 million, an increase of 3.93% compared to the previous year's $40.39 million. Losses were -$16.69 million, 38.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Exagen stock is "Strong Buy." The 12-month stock price forecast is 26.60, which is an increase of 78.16% from the latest price.

Price Target
$26.60
(78.16% upside)
Analyst Consensus: Strong Buy